Alain Vergnenègre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alain Vergnenègre has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
C. Combescure
CHU Montpellier Universite´Montpellier 1
2 shared publications- Christos Chouaid
Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, Créteil, France
2 shared publications P. Fournel
CHU Saint-Etienne
2 shared publications- Pierre-Marie Preux
Inserm U1094, IRD UMR270, Univ. Limoges, CHU Limoges, EpiMaCT - Epidemiology of chronic diseases in tropical zone, Institute of Epidemiology and Global Health – Michel Dumas, OmegaHealth, Limoges, France
2 shared publications B. Housset
1 shared publicationC. Daniel
1 shared publication
Latest Publications
- Open Access
- 25 May 2006
- Published by Elsevier in Annals of Oncology
- Vol. 17 (8) , 1269-1274
Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95–01)
Background: We conducted an economic analysis of a phase III clinical trial comparing sequential radiochemotherapy (RT-CT) with concurrent RT-CT in patients with locally advanced non-small-cell lung cancer. Patients and methods: The trial was a randomized multicenter study comparing three cycles of chemotherapy (arm A) followed by radiotherapy against an RT-CT combination (two cycles of platinum etoposide) followed by two cycles of platinum-vinorelbine (arm B). The economic analysis adopted the payer's perspective and only included direct costs. Costs (€, 1996–2003) were recorded until the cut-off date. A cost minimization analysis and a sensitivity analysis were carried out. Results: Data from 173 patients were used in the economic study. Protocol costs tended to be higher in arm B, while relapse costs were significantly higher in arm A. The total number of hospital days was higher in arm B. The average total cost per patient was €16 074 in arm A and €15 245 in arm B (P = 0.15). The cost minimization analysis favored arm B. This advantage persisted in the sensitivity analysis. Conclusions: Concurrent RT-CT was not the more costly strategy in this phase III trial, despite lengthier hospitalization for toxicity. Other studies of similar design are needed to confirm these results in future randomized trials.
- 25 May 2006
- Published by Elsevier in Annals of Oncology
- Vol. 17 (8) , 1269-1274
Open AccessCost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95–01)
Background: We conducted an economic analysis of a phase III clinical trial comparing sequential radiochemotherapy (RT-CT) with concurrent RT-CT in patients with locally advanced non-small-cell lung cancer. Patients and methods: The trial was a randomized multicenter study comparing three cycles of chemotherapy (arm A) followed by radiotherapy against an RT-CT combination (two cycles of platinum etoposide) followed by two cycles of platinum-vinorelbine (arm B). The economic analysis adopted the payer's perspective and only included direct costs. Costs (€, 1996–2003) were recorded until the cut-off date. A cost minimization analysis and a sensitivity analysis were carried out. Results: Data from 173 patients were used in the economic study. Protocol costs tended to be higher in arm B, while relapse costs were significantly higher in arm A. The total number of hospital days was higher in arm B. The average total cost per patient was €16 074 in arm A and €15 245 in arm B (P = 0.15). The cost minimization analysis favored arm B. This advantage persisted in the sensitivity analysis. Conclusions: Concurrent RT-CT was not the more costly strategy in this phase III trial, despite lengthier hospitalization for toxicity. Other studies of similar design are needed to confirm these results in future randomized trials.
- 28 February 2006
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 23 (1) , 3S47-3S60
Les outils de l’évaluation des soins
- 28 February 2006
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 23 (1) , 3S47-3S60
Les outils de l’évaluation des soins
- 1 February 2006
- Vol. 23, 3S47-60
[Tools for assessing healthcare delivery].
Assessing the quality of care has become an essential part of the medical process. In France, the Professional Practice Evaluation requires a sound knowledge of these techniques. The different tools that can be used to carry out quality assessment are presented, with their specific applications. Two main categories can be used. The first are information synthesis techniques such as consensus conferences, practice guidelines, and panellist's appropriateness rating. The second category is based on comparison to a reference: clinical audit, targeted clinical audit, or appropriateness evaluation protocols. Other, less commonly employed approaches include a problem solving approach, which is often included in total quality management, clinical care pathway, risk management, mortality morbidity conference, adverse event monitoring, and statistical process control charts. These tools will be widely used in the next few years, because the recent changes in French law could increase their use. A good knowledge of these techniques is needed in order to improve quality assessment.
- 1 February 2006
- Vol. 23, 3S47-60
[Tools for assessing healthcare delivery].
Assessing the quality of care has become an essential part of the medical process. In France, the Professional Practice Evaluation requires a sound knowledge of these techniques. The different tools that can be used to carry out quality assessment are presented, with their specific applications. Two main categories can be used. The first are information synthesis techniques such as consensus conferences, practice guidelines, and panellist's appropriateness rating. The second category is based on comparison to a reference: clinical audit, targeted clinical audit, or appropriateness evaluation protocols. Other, less commonly employed approaches include a problem solving approach, which is often included in total quality management, clinical care pathway, risk management, mortality morbidity conference, adverse event monitoring, and statistical process control charts. These tools will be widely used in the next few years, because the recent changes in French law could increase their use. A good knowledge of these techniques is needed in order to improve quality assessment.
- 31 March 2005
- Published by Elsevier in Lung Cancer
- Vol. 47 (3) , 395-404
Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer: A phase II trial conducted by the Groupe Français de Pneumo-Cancérologie (GFPC)
- 31 March 2005
- Published by Elsevier in Lung Cancer
- Vol. 47 (3) , 395-404
Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer: A phase II trial conducted by the Groupe Français de Pneumo-Cancérologie (GFPC)
- 30 September 2004
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 21 (4) , 47-55
L’analyse coût-efficacité : un guide de lecture
- 30 September 2004
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 21 (4) , 47-55
L’analyse coût-efficacité : un guide de lecture
- 1 September 2004
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 21 (4) , 56-62
Les recommandations de pratique clinique : un guide de lecture
- 1 September 2004
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 21 (4) , 56-62
Les recommandations de pratique clinique : un guide de lecture
- 30 June 2004
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 21 (3) , 501-510
Les composantes du coût des stratégies de prise en charge du cancer du poumon en France
- 30 June 2004
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 21 (3) , 501-510
Les composantes du coût des stratégies de prise en charge du cancer du poumon en France
- 1 June 2004
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 21, 165
Aspects médico-économiques de la pneumologie
- 1 June 2004
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 21, 165
Aspects médico-économiques de la pneumologie
- Open Access
Economic Evaluation of Epilepsy in Kiremba (Burundi): A Case–Control Study
Summary: Purpose: Epilepsy is a common disease whose prevalence across Africa is extremely variable (from 5 to 74‰). Its social and economic consequences in this continent are not well established. The objective of this study was to compare the cost of care of patients with epilepsy with that of controls in the commune of Kiremba in Burundi. Methods: The survey was carried out in the commune of Kiremba from March 1, 2001, to April 30, 2001. A sample of cases (patients with epilepsy) and controls was taken from the general population. The economic analysis was conducted from the viewpoint of the patient. Data collected were direct medical costs (consultations, admissions to hospital, complementary examinations, treatments) and indirect costs (evaluated from the number of days of family life disrupted). Results: In this study, 1,056 patients were included (352 patients with epilepsy and 704 controls). The total annual cost of patients with epilepsy was US$11.0 against US$7.3 for controls (p = 0.03). The indirect costs represented 75.8% of the total cost. For the people with epilepsy that took antiepileptic treatment (n = 18), the annual average total cost became US$48.4. The number of disrupted days was 10.2 days (SD, 18.7 days) for the treated patients with epilepsy and 2.0 days (SD, 9.0 days) for the untreated ones (p < 0.001). Conclusions: Epilepsy was responsible for an extra cost: an increased direct cost along with more disruption of family life. This extra cost remained after adjustment for use of health care and antiepileptic treatments. Various measures could be envisioned to reduce the impact of indirect costs.
Open AccessEconomic Evaluation of Epilepsy in Kiremba (Burundi): A Case–Control Study
Summary: Purpose: Epilepsy is a common disease whose prevalence across Africa is extremely variable (from 5 to 74‰). Its social and economic consequences in this continent are not well established. The objective of this study was to compare the cost of care of patients with epilepsy with that of controls in the commune of Kiremba in Burundi. Methods: The survey was carried out in the commune of Kiremba from March 1, 2001, to April 30, 2001. A sample of cases (patients with epilepsy) and controls was taken from the general population. The economic analysis was conducted from the viewpoint of the patient. Data collected were direct medical costs (consultations, admissions to hospital, complementary examinations, treatments) and indirect costs (evaluated from the number of days of family life disrupted). Results: In this study, 1,056 patients were included (352 patients with epilepsy and 704 controls). The total annual cost of patients with epilepsy was US$11.0 against US$7.3 for controls (p = 0.03). The indirect costs represented 75.8% of the total cost. For the people with epilepsy that took antiepileptic treatment (n = 18), the annual average total cost became US$48.4. The number of disrupted days was 10.2 days (SD, 18.7 days) for the treated patients with epilepsy and 2.0 days (SD, 9.0 days) for the untreated ones (p < 0.001). Conclusions: Epilepsy was responsible for an extra cost: an increased direct cost along with more disruption of family life. This extra cost remained after adjustment for use of health care and antiepileptic treatments. Various measures could be envisioned to reduce the impact of indirect costs.
- 1 October 2001
- Vol. 18 (5) , 507-16
[Evaluation of respiratory intensive care units at pneumology services].
Audits should be conducted in respiratory intensive care units (ICU) as in all other ICU using patient-specific indicators to assess medical activity and quality of care. However, other criteria, such as those developed by the SRLF ("Société de Réanimation de Langue Française"), should also be used. These criteria include the description of the patients previous health status, prognosis of underlying diseases, the SAPS I or SAPS II severity score at admission, the omega or TISS therapeutic scores, and the PRN index of health care burden. Medial and administrative audits are conducted using diagnosis-related groups (DRG) and case mix classification. The DRGs are used to establish an aggregate index of activity (ISA points) which contribute to the complex mechanism of budget allowance. Unfortunately, the French DRG case mix system does not provide an appropriate description of the costs of ICU stays. One of the special features of respiratory ICUs is related to patient flow. Patients are referred from a respiratory unit and discharged to a respiratory unit or a respiratory rehabilitation center. Readmissions are frequent. Many patients are also admitted only for diagnosis or a respiratory procedure requiring close surveillance. The SRLF criteria, which take into consideration all of these features, should always be used for the evaluation of quality of care. The French Society of Lung Disease (SPLF) has proposed specific standards of quality for respiratory ICU. We present here examples issuing for the ICU of the Hôtel-Dieu Hospital in Paris. The results show that non-specific national indicators, in combination with other indicators specific for respiratory ICU, provide appropriate audit data.
- 1 October 2001
- Vol. 18 (5) , 507-16
[Evaluation of respiratory intensive care units at pneumology services].
Audits should be conducted in respiratory intensive care units (ICU) as in all other ICU using patient-specific indicators to assess medical activity and quality of care. However, other criteria, such as those developed by the SRLF ("Société de Réanimation de Langue Française"), should also be used. These criteria include the description of the patients previous health status, prognosis of underlying diseases, the SAPS I or SAPS II severity score at admission, the omega or TISS therapeutic scores, and the PRN index of health care burden. Medial and administrative audits are conducted using diagnosis-related groups (DRG) and case mix classification. The DRGs are used to establish an aggregate index of activity (ISA points) which contribute to the complex mechanism of budget allowance. Unfortunately, the French DRG case mix system does not provide an appropriate description of the costs of ICU stays. One of the special features of respiratory ICUs is related to patient flow. Patients are referred from a respiratory unit and discharged to a respiratory unit or a respiratory rehabilitation center. Readmissions are frequent. Many patients are also admitted only for diagnosis or a respiratory procedure requiring close surveillance. The SRLF criteria, which take into consideration all of these features, should always be used for the evaluation of quality of care. The French Society of Lung Disease (SPLF) has proposed specific standards of quality for respiratory ICU. We present here examples issuing for the ICU of the Hôtel-Dieu Hospital in Paris. The results show that non-specific national indicators, in combination with other indicators specific for respiratory ICU, provide appropriate audit data.